HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis

Hepatology

Volumn 38, Issue 1, 2003, Pages 86-95

  Roche, Bruno ^a   Feray, Cyrille ^a   Gigou, Michele ^a   Roque Afonso, Anne Marie ^a   Arulnaden, Jean Louis ^a   Delvart, Valerie ^a   Dussaix, Elisabeth ^a   Guettier, Catherine ^a   Bismuth, Henri ^a   Samuel, Didier ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS DNA; HEPATITIS B(E) ANTIGEN; IVHEBEX; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOPROPHYLAXIS; LIVER BIOPSY; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REINFECTION; SUPERINFECTION; SURVIVAL; VIRUS REPLICATION;

EID: 0037785048     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50294     Document Type: Article

References (43)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. HEPATOLOGY 1991;13:619-626.
2. O'Grady JG, Smith HM, Davies S, Daniels HM, Donaldson PT, Tan KC, Portmann B, et al. Hepatitis B virus re-infection after liver transplantation: serological and clinical implications. J Hepatol 1992;14:104-111.
3. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
5. König V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, Bechstein WO, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58:553-559.
6. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. HEPATOLOGY 2000;32:1189-1195.
7. Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, Cirera I, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. HEPATOLOGY 2000;31:496-501.
8. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, Lionetti R, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. HEPATOLOGY 2002;35:176-181.
9. Dodson SF, De Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000;6:434-439.
10. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, De Man RA, Bassendine M, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-894.
11. McGory RW, Ishitani M, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell S, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
12. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. HEPATOLOGY 1996;24:1327-1333.
13. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against re-infection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-1215.
14. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, et al. High pre-treatment serum hepatitis B virus itre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715-721.
15. The Lamivudine Transplant Group, Perrillo R, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, et al. A Multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. HEPATOLOGY 2001;33:424-432.
16. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu I, Yersiz H, Goss JA, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. HEPATOLOGY 1998;28:585-589.
17. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus pre coce mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl 1999;5:512-519.
18. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, Eggen HJ, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl 1999;5:520-525.
19. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 1999;5:491-496.
20. Rosenau J, Bahr M, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
21. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
22. Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M, David MF, et al. Pre-transplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. HEPATOLOGY 1994;19:6-12.
23. Scotto J, Hadchouel M, Hery C, Yvart J, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in serum by a single spot hybridization technique: comparison with results of other viral markers. HEPATOLOGY 1983;3:279-284.
24. Deny P, Lecot C, Jeantils V, Ovaguimian L, Krivitzky A, Brechot C. Polymerase chain reaction-based detection of hepatitis D virus genome in patients infected with human immunodeficiency virus. J Med Virol 1993;39:214-218.
25. Mercier B, Burlot L, Ferec C. Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay. J Virol Methods 1999;77:1-9.
26. Marusawa H, Uemoro S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. HEPATOLOGY 2000;31:488-495.
27. Lerut JP, Donataccio M, Ciccarellio O, Roggin F, Jamart J, Laterre PF, Cornu C, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999;30:706-714.
28. Gugenheim J, Crafa F, Fabiani P, Goubaux B, Ouzan D, Mouiel J. Long term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients. Transplant Proc 1993;25:1349-1350.
29. Kiyasu PK, Ishitani MB, McGory RW, Gaffey MJ, Dickson RC, Caldwell SH, Stevenson W, et al. Prevention of hepatitis B recurrence after a second liver transplant - the role of maintenance polyclonal HBIg therapy. Transplantation 1994;58:954-956.
30. Ishiani M, McGory R, Dickson R, Caldwell S, Bickson S, McCullough C, Pruett TL, et al. Re-transplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 1997;64:410-414.
31. Roche B, Samuel D, Feray C, Majno P, Gigou M, Reynes M, Bismuth H. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl 1999;5:166-174.
32. Naumann U, Protzer-Knolle U, Berg T, Leder K, Lobeck H, Bechstein WO, Gerken G, et al. A pretransplant infection with pre coce mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high-dose anti-hepatitis B virus surface antigen immunoprophylaxis. HEPATOLOGY 1997;26:478-484.
33. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-113.
34. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. HEPATOLOGY 1995;21:333-339.
35. Rizzetto M. The delta agent. HEPATOLOGY 1983;3:729-737,
36. Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P, Bismuth H, et al. Persistent hepatitis B virus infection of mononuclear cells without concomitant liver infection: the liver transplant model. Transplantation 1990;49:1155-1158.
37. Brind A, Jiang J, Samuel D, Gigou M, Feray C, Brechot C, Kremsdorf D. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997;26:228-235.
38. Carman WF, Trautwein C, Van Deursen JV, Colman K, Dornan E, McIntyre G, Waters J, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. HEPATOLOGY 1996;24:489-493.
39. Trautwein C, Schrem H, Tillmann HL, Kubica S, Walker D, Boker KHW, Maschek HJ, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. HEPATOLOGY 1996;24:482-488.
40. Ghany HG, Ayola B, Villamil FG, Gish RG, Roster S, Vierling JM, Lok ASF. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. HEPATOLOGY 1998;27:213-222.
41. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. HEPATOLOGY 1998;27:254-263.
42. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. HEPATOLOGY 1998;28:555-561.
43. Roque Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-99.